Last updated: October 17, 2026
Good Sense omeprazole is a private-label over-the-counter proton-pump inhibitor positioned around low price, delayed release, and short-course heartburn treatment. Its commercial value is driven less by active-ingredient exclusivity than by manufacturing cost, enteric protection, shelf stability, packaging, retailer economics, and consumer adherence.
The product name can cover different National Drug Code listings and dosage forms. The analysis below applies to the common U.S. 20-mg delayed-release omeprazole capsule or tablet sold under the Good Sense private label. Exact excipients, manufacturer, and label claims must be confirmed against the applicable NDC and current DailyMed labeling.
What is Good Sense omeprazole?
Good Sense omeprazole is an OTC delayed-release omeprazole product used for frequent heartburn. Omeprazole suppresses gastric acid by inhibiting the gastric H+/K+-ATPase in parietal cells. The delayed-release design protects omeprazole from degradation in the stomach and releases the drug in the higher-pH environment of the small intestine.
| Product attribute |
Commercial profile |
| Brand |
Good Sense |
| Active ingredient |
Omeprazole |
| Common strength |
20 mg delayed-release dose |
| U.S. regulatory pathway |
OTC drug monograph pathway |
| Therapeutic category |
Proton-pump inhibitor |
| Typical indication |
Frequent heartburn, generally occurring two or more days per week |
| Common dosage form |
Delayed-release capsule or tablet |
| Primary channel |
Retail pharmacy, discount retail, e-commerce, and private-label programs |
| Patent position |
Core omeprazole composition patents have expired |
| Main competitive factors |
Unit cost, coating performance, retailer margin, packaging, and supply reliability |
FDA OTC labeling generally directs consumers to take omeprazole once daily before eating for a limited treatment period. The product is not intended to provide immediate relief from occasional heartburn. [1]
What excipients are used in Good Sense omeprazole?
The exact excipient system depends on the dosage form and contract manufacturer. Omeprazole delayed-release products commonly use a multiparticulate pellet system or a coated tablet system.
Common capsule excipients
A delayed-release omeprazole capsule may contain:
- Hypromellose or another polymeric coating material
- Sugar spheres or other inert starter cores
- Talc
- Methacrylic acid copolymer
- Polyethylene glycol
- Polysorbate 80
- Sodium hydroxide or another alkalizing agent
- Meglumine or an alternative stabilizer
- Titanium dioxide
- Gelatin or a vegetarian capsule shell
- Colorants
These ingredients are not interchangeable from a development perspective. Omeprazole is acid-labile, so the formulation typically requires an alkaline microenvironment, a protective seal coat, and an enteric polymer layer.
Common tablet excipients
A delayed-release tablet may use:
- Microcrystalline cellulose
- Mannitol or lactose
- Crospovidone
- Povidone
- Colloidal silicon dioxide
- Magnesium stearate
- Hypromellose
- Methacrylic acid copolymer
- Polyethylene glycol
- Talc
- Titanium dioxide
A tablet platform can reduce capsule-shell costs and provide a smaller or more robust unit dose. It can also create more demanding coating and compression requirements.
Why the excipient system matters
The principal technical objective is to keep omeprazole stable during manufacture, storage, and gastric transit. The formulation must control:
- Exposure to moisture and acidic conditions.
- Uniformity of the drug layer on the pellet or tablet core.
- Integrity of the enteric coat.
- Release at the appropriate intestinal pH.
- Dissolution performance after accelerated and long-term storage.
Excipient selection affects bioavailability, dissolution, manufacturing yield, stability, and the probability of an FDA quality deficiency. The lowest-cost excipient package is not necessarily the lowest-cost commercial formulation if it produces coating defects, batch failures, or shorter shelf life.
How strong is the excipient strategy for Good Sense omeprazole?
The likely strategy is a mature, conventional delayed-release platform rather than a highly differentiated drug-delivery system. Its strengths are cost control, established regulatory precedent, and broad supplier availability.
| Excipient strategy |
Commercial benefit |
Principal risk |
| Multiparticulate enteric-coated pellets |
Strong gastric protection and established technology |
Multiple coating steps and higher process complexity |
| Enteric-coated tablet |
Lower capsule dependence and potential packaging efficiency |
Compression and coating can affect release performance |
| Alkaline stabilizer system |
Protects omeprazole from acid degradation |
Changes in alkalinity can affect stability and dissolution |
| Hypromellose-based coating |
Broad supplier base and established use |
Moisture sensitivity and process-control requirements |
| Methacrylic acid copolymer |
Established enteric release profile |
Polymer supply and coating uniformity |
| Standard gelatin capsule |
Low cost and high manufacturing familiarity |
Animal-origin and shell-moisture considerations |
| Vegetarian capsule |
Supports dietary and market-positioning claims |
Higher material cost and possible supply constraints |
The strongest commercial formulation is generally the one that achieves reliable enteric release with the fewest coating layers, lowest solvent burden, and highest manufacturing yield. A meaningful formulation advantage would require measurable improvement in stability, dissolution, throughput, or cost.
What commercial opportunities exist for Good Sense omeprazole excipients?
Lower-cost enteric coating systems
The largest near-term opportunity is cost reduction in the enteric coating process. Manufacturers can evaluate:
- Higher-solids aqueous coating systems
- Reduced coating weight
- Faster drying cycles
- Lower-cost polymer suppliers
- Directly compressed cores with fewer intermediate layers
- Improved anti-tacking systems
Any change must preserve acid resistance and intestinal release. For an OTC product, a coating change that alters dissolution may require regulatory documentation and could create a new product-specific regulatory risk.
Excipient dual sourcing
Good Sense is exposed to supply continuity for enteric polymers, coating agents, alkalizing agents, capsule shells, and colorants. Dual sourcing can reduce disruption risk, especially for:
- Methacrylic acid copolymers
- Hypromellose
- Talc
- Titanium dioxide alternatives
- Gelatin or vegetarian capsule shells
- Polyethylene glycol
The commercial opportunity for excipient suppliers is strongest where a material has both regulatory precedent and a credible second-source qualification package.
Capsule-shell substitution
A switch from gelatin to hypromellose capsules can support vegetarian positioning and reduce exposure to animal-origin supply constraints. The opportunity is commercially relevant, but the change can affect moisture transfer, fill-weight control, disintegration, and shell performance.
For a value-oriented private-label product, vegetarian capsules may increase cost unless the retailer can support a premium or broader distribution rationale.
Improved moisture protection
Omeprazole products can benefit from high-barrier blister packaging, desiccants, and improved bottle-closure systems. Packaging is part of the stability strategy because moisture can compromise the enteric coating and active ingredient.
Commercial opportunities include:
- Unit-dose blister packs
- Smaller-count travel packs
- High-barrier bottles
- Desiccant-integrated closures
- Child-resistant packaging with easier senior access
- Reduced-headspace packaging
Retailers may favor packaging innovations that reduce returns, extend shelf life, or improve shelf presentation even when the drug formulation is unchanged.
What formulation patents protect omeprazole products?
The original omeprazole patent estate included composition, formulation, salt, process, and use claims. Core composition and early formulation protection has expired in the United States. The commercially relevant protection for a current Good Sense product is therefore unlikely to be a fundamental omeprazole patent.
Potentially relevant rights can still arise from:
- Specific enteric-coated pellet architectures
- New stabilizer combinations
- Modified-release profiles
- Alternative salts or polymorphs
- Manufacturing processes
- Packaging systems
- Combination products
- Pediatric or specialty dosage forms
A third-party patent review remains important if the manufacturer adopts a new coating composition, unusual release profile, or proprietary manufacturing process. A routine omeprazole delayed-release product generally has a weaker patent position than a novel formulation platform.
What is the FDA and Orange Book status of Good Sense omeprazole?
Good Sense omeprazole is typically marketed as an OTC product under the FDA nonprescription framework rather than through an abbreviated new drug application that relies on a branded prescription reference product.
The FDA OTC monograph system allows compliant products to be marketed without a product-specific FDA approval order when the active ingredient, dosage form, labeling, and conditions of use satisfy the applicable monograph requirements. The FDA’s OTC monograph framework is now governed by the Over-the-Counter Monograph Drug User Fee Program and the CARES Act-era administrative order system. [2]
The Orange Book primarily lists approved prescription drug products and does not function as the principal exclusivity registry for ordinary OTC monograph omeprazole products. Consequently:
- An Orange Book listing should not be assumed for every Good Sense SKU.
- Paragraph IV litigation is generally not the central pathway for a compliant OTC monograph product.
- Product-specific approval status depends on the NDC, dosage form, labeling, and manufacturer.
- Patent risk should be assessed through the relevant product and process patent landscape, not only Orange Book listings.
When does omeprazole lose exclusivity?
The core omeprazole exclusivity period has already expired in the United States. Generic and OTC competition has existed for years, including products from major manufacturers and retailer-controlled private-label suppliers.
| Exclusivity category |
Current commercial position |
| Core active-ingredient patents |
Expired |
| Original prescription exclusivity |
Expired |
| Basic delayed-release formulation protection |
Largely expired or commercially bypassed |
| OTC monograph access |
Available to compliant manufacturers |
| New formulation patents |
Possible, but product-specific |
| Pediatric exclusivity |
Not a meaningful barrier for standard adult OTC products |
| Biosimilar exclusivity |
Not applicable |
Omeprazole is a small molecule, so biosimilar risk does not apply. The competitive threat is conventional generic and private-label substitution.
Which companies compete with Good Sense omeprazole?
The competitive market includes:
- Store brands sold by pharmacy and mass-merchandise chains
- Perrigo and other private-label manufacturers
- Dr. Reddy’s Laboratories
- ANI Pharmaceuticals
- Prasco Laboratories
- Viatris and related generic channels
- CVS Health, Walgreens, Walmart, Amazon, and other retailer-controlled brands
- Branded OTC products such as Prilosec OTC
Competition is based on retail price, count size, packaging, retailer margin, supply reliability, and consumer familiarity. A private-label omeprazole product can gain share without a differentiated formulation if it delivers consistent quality and materially lower shelf price.
What generic launch risks exist for Good Sense omeprazole?
Generic entry risk is structurally high because:
- The active ingredient is off patent.
- The technology is mature.
- Multiple manufacturers have relevant manufacturing experience.
- The FDA pathway is established.
- Consumers can switch among therapeutically similar products.
- Retailers can change suppliers with limited brand disruption.
The main barriers are operational rather than patent-based. They include validated enteric-release performance, product stability, manufacturing capacity, FDA compliance, raw-material qualification, and retailer service levels.
A new entrant can compete through a lower-cost pellet process, improved packaging, larger count sizes, or a supply agreement with a national retailer. The strongest defense for an incumbent private-label supplier is usually cost and execution rather than exclusivity.
How does Good Sense omeprazole compare with competing acid reducers?
| Product type |
Active ingredient |
Release or dosing profile |
Excipient opportunity |
Competitive position |
| Good Sense omeprazole |
Omeprazole |
Delayed release, generally once daily |
Enteric coating, stabilizers, packaging |
Low-cost PPI |
| Esomeprazole OTC |
Esomeprazole |
Delayed release, generally once daily |
Similar enteric protection requirements |
Branded and private-label competition |
| Lansoprazole OTC |
Lansoprazole |
Delayed release |
Pellet or capsule coating |
Established alternative PPI |
| Famotidine |
Famotidine |
Immediate-release tablet |
Conventional tablet excipients |
Faster-acting H2 blocker alternative |
| Calcium carbonate antacid |
Calcium carbonate |
Immediate neutralization |
Chewable tablet or suspension system |
Rapid-relief competitor |
Omeprazole’s formulation complexity is higher than that of conventional antacid tablets because the product must protect an acid-labile active ingredient and control release beyond the stomach.
What licensing and supply-chain opportunities exist?
Licensing opportunities are most likely to involve manufacturing technology rather than the omeprazole molecule. Potential structures include:
- Contract manufacturing of delayed-release pellets
- Licensing of high-solids aqueous enteric coating technology
- Private-label supply agreements
- Excipient supply contracts with second-source rights
- Packaging licenses for high-barrier blister systems
- Technology-transfer agreements for tablet-based delayed release
- Retailer-exclusive pack sizes or formulations
The most valuable commercial asset is a validated, scalable process with low coating loss, high batch yield, and stable dissolution performance. A formulation patent adds value only if it creates a defensible cost, quality, or regulatory advantage.
What is the revenue exposure for Good Sense omeprazole?
Good Sense omeprazole is likely a lower-margin, higher-volume product. Revenue exposure is concentrated in:
- Retailer shelf placement
- Promotional pricing
- Seasonal heartburn demand
- Supplier continuity
- Private-label conversion from branded products
- Count-size economics
- Online search and subscription purchasing
A supplier with a national retail contract can generate meaningful volume despite limited per-unit pricing power. Margin compression is likely when multiple suppliers qualify for the same retailer program.
The principal value drivers are:
- Cost per sellable dose.
- Batch yield.
- Shelf-life performance.
- Retailer fill rate.
- Packaging cost.
- Ability to support multiple pack sizes.
- Speed of regulatory change control.
What is the patent strength of Good Sense omeprazole?
The patent strength is low for the standard product and moderate only where a manufacturer owns a specific, enforceable formulation or process claim.
| Patent category |
Estimated relevance |
| Omeprazole composition patent |
Low; expired |
| Basic delayed-release concept |
Low; mature technology |
| Specific enteric coating composition |
Moderate if claim scope is narrow and unexpired |
| Manufacturing process |
Moderate if difficult to design around |
| Packaging and moisture-control technology |
Low to moderate |
| New combination or dosage form |
Product-specific |
| Biosimilar exclusivity |
None |
Freedom-to-operate analysis should focus on active formulation and process patents, not the expired core omeprazole estate.
Key Takeaways
- Good Sense omeprazole competes primarily through price, supply reliability, and retailer economics.
- The core omeprazole patent estate no longer creates a meaningful exclusivity barrier.
- The critical formulation technology is the enteric protection system and alkaline stabilization strategy.
- Excipients create commercial opportunities through coating-cost reduction, dual sourcing, moisture protection, and capsule substitution.
- Orange Book and Paragraph IV analysis is less central for a standard OTC monograph product than for an approved prescription generic.
- Biosimilar risk does not apply because omeprazole is a small molecule.
- Patent strength is low for a routine delayed-release product and higher only for a specific, unexpired formulation or manufacturing claim.
- The largest business risks are manufacturing failure, supply interruption, dissolution nonconformance, retailer switching, and margin compression.
FAQs
Can Good Sense omeprazole be reformulated without new patent protection?
Yes. A manufacturer can change excipients or manufacturing processes if the resulting product remains compliant with applicable FDA requirements and does not infringe an enforceable third-party patent.
Are enteric polymers the most important excipients in omeprazole?
They are among the most important. The stabilizer system, seal coat, moisture control, and enteric polymer must work together to maintain acid resistance and intestinal release.
Does omeprazole require a biosimilar strategy?
No. Omeprazole is a synthetic small molecule. Competition occurs through generic, OTC monograph, and private-label pathways rather than biosimilar regulation.
Can a retailer obtain an exclusive omeprazole formulation?
A retailer can negotiate an exclusive supply arrangement or exclusive pack configuration. Exclusivity over the active ingredient is not commercially realistic because omeprazole is off patent and widely available.
What would create the strongest commercial differentiation for Good Sense omeprazole?
The strongest opportunities are lower manufacturing cost, longer shelf life, more reliable enteric release, improved moisture protection, vegetarian capsules, and packaging that lowers distribution or consumer-use costs.
References
-
U.S. Food and Drug Administration. (n.d.). OTC heartburn treatment labeling and omeprazole drug facts information. FDA.
-
U.S. Food and Drug Administration. (n.d.). Over-the-counter monograph drug user fee program and OTC monograph order requests. FDA.
-
U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
-
U.S. National Library of Medicine. (n.d.). DailyMed: Omeprazole delayed-release capsule and tablet labeling. National Library of Medicine.
-
U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. FDA.
